Avagene Therapeutics is a Philadelphia-based small business developing automated viral-vector manufacturing tools for academic labs, vector cores, and emerging biotechs — with a clear glidepath to clinical readiness.
Shorter iteration cycles, higher reproducibility, and lower per-batch cost for adherent AAV production — without forcing a platform switch that penalizes startups and academic groups with comparability work.
Avagene's focus is scientific feasibility, validated analytics, and clean tech transfer. The company is run leanly, with wet-lab operations executed in collaboration with Temple University and a licensed platform technology from Appraiseye Inc.
Founder & President
Physician-scientist and biotech entrepreneur working at the intersection of neural repair, clinical neurosurgery research, and AI-enabled automation for operative workflows and cell & gene therapy manufacturing.
Founder & President of Avagene Therapeutics Inc. Chief Executive Officer of Appraiseye Inc. Research Associate in Neurosurgery at Thomas Jefferson University. Postdoctoral fellow at the Shriners Pediatric Research Center, Temple University, with published work on spinal cord injury, neuromodulation, and circuit plasticity.
MBBS, St George's, University of London · MSc Cognitive & Clinical Neuroscience (Distinction), Goldsmiths · BA Psychology, Boston University.
1701 Locust St, Unit 1906, Philadelphia, PA 19103 (PA-003). Systems engineering, vision-AI software, EBR schema, design controls, and integrated verification.
Medical Education & Research Building, 3500 N Broad St, Philadelphia, PA 19140 (PA-003). Wet-lab execution under Dr. George M. Smith at the Shriners Pediatric Research Center, via Temple's Innovation Nest (iNest) with access to BL2+ viral core and shared instrumentation.
The Bodhi background IP (PCT/US2025/019046; ISR/WO on file, June 2025) is owned by Appraiseye Inc. Avagene holds an exclusive license as to the field of AAV manufacturing automation on the Bodhi platform for the purposes of this SBIR Phase I project, with authority to permit Temple University to practice the IP under the subaward.
Project data first produced under the award will be marked with the SBIR/STTR data rights legend and protected from public release consistent with applicable law and policy.